A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine

Han, Hee Dong; Song, Chung Kil; Park, Yong Sung; Noh, Kyung Hee; Kim, Jin Hee; Hwang, Taewon; Kim, Tae Woo; Shin, Byung Cheol

doi:10.1016/j.ijpharm.2007.08.014

Cited by 108 publications

(42 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chitosan nanoparticles have been previously demonstrated to be highly efficient in delivering siRNA into the tumor mass via the enhanced permeability and retention effect (19)(20)(21). Sixteen days after tumor challenge, mice received adoptive transfer of E7-specific CTLs ( Figure 9A).…”

Section: Nanog Expression In Tumor Cells Correlates With Stage and Prmentioning

confidence: 99%

“…siRNA was delivered in vitro into 6-well plates at a dose of 300 pmol per well using Lipofectamine 2000 (Invitrogen). siRNA was delivered into mice after formulation with chitosan nanoparticles as described previously (20). Briefly, tripolyphosphate (0.25% w/v) and siRNA (1 μg/μl) were combined in RGD-chitosan solution, and the mixture was incubated at 4°C for 40 minutes.…”

Section: Figurementioning

confidence: 99%

See 1 more Smart Citation

Nanog signaling in cancer promotes stem-like phenotype and immune evasion

Noh¹,

Kim²,

Song³

et al. 2012

J. Clin. Invest.

Self Cite

175

220

View full text Add to dashboard Cite

Adaptation of tumor cells to the host is a major cause of cancer progression, failure of therapy, and ultimately death. Immune selection drives this adaptation in human cancer by enriching tumor cells with a cancer stem cell-like (CSC-like) phenotype that makes them resistant to CTL-mediated apoptosis; however, the mechanisms that mediate CSC maintenance and proliferation are largely unknown. Here, we report that CTL-mediated immune selection drives the evolution of tumor cells toward a CSC-like phenotype and that the CSC-like phenotype arises through the Akt signaling pathway via transcriptional induction of Tcl1a by Nanog. Furthermore, we found that hyperactivation of the Nanog/Tcl1a/Akt signaling axis was conserved across multiple types of human cancer. Inhibition of Nanog in a murine model of colon cancer rendered tumor cells susceptible to immune-mediated clearance and led to successful, long-term control of the disease. Our findings establish a firm link among immune selection, disease progression, and the development of a stem-like tumor phenotype in human cancer and implicate the Nanog/Tcl1a/Akt pathway as a central molecular target in this process.

show abstract

Section: Nanog Expression In Tumor Cells Correlates With Stage and Prmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

Nanog signaling in cancer promotes stem-like phenotype and immune evasion

Noh¹,

Kim²,

Song³

et al. 2012

J. Clin. Invest.

Self Cite

175

220

View full text Add to dashboard Cite

show abstract

“…They all rely on the persistence, activation, and expansion of antigen-specific T cells after chemotherapy. In several animal models, combination of radiation or chemotherapy with different cancer vaccines indeed resulted in an increased frequency of antigen-specific T cells that was associated with antitumor effects (28)(29)(30). However, in mouse experiments, chemotherapy is usually administered only once and does not cause substantial immune suppression.…”

Section: Discussionmentioning

confidence: 99%

A Direct Synergistic Effect of Immunotherapy and Chemotherapy as a New Paradigm in Treatment of Breast Cancer

Gabrilovich¹

2010

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. REPORT DATE / /2010 2. REPORT TYPE Final 3. DATES COVERED 1 Apr 2007-31 Mar 2010 TITLE AND SUBTITLEA direct synergistic effect of immunotherapy and chemotherapy 5a. CONTRACT NUMBERW81XWH-07-1-0315as a new paradigm in treatment of breast cancer 5b. GRANT NUMBER BC061707 (IDEA)5c. PROGRAM ELEMENT NUMBER AUTHOR(S)Dmitry Gabrilovich 5d. PROJECT NUMBER 5e. TASK NUMBER 5f. WORK UNIT NUMBER PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER Mofftt Cancer CenterTampa, FL, SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and ateriel Fort Detrick, Maryland SPONSOR/MONITOR'S REPORT 21702-5012 NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for public release; distribution unlimited SUPPLEMENTARY NOTES ABSTRACTTreatment of patients with advanced stages of breast cancer remains an unresolved clinical problem. The main objectives of this study are to determine whether immunotherapy sensitizes tumor to chemotherapy and to identify some of the main mechanisms of this effect. We investigated the possibility of a direct synergy between immunotherapy and chemotherapy in vitro. We found that pre-treatment of tumor target cells with doxorubicin or paclitaxel significantly increased cytotoxic effect of T-lymphocytes. Importantly, that effect was antigen-specific, since it was observed only in tumor cells loaded with specific but not a control peptide. In contrast, pre-treatment of splenocytes did not result in enhancement of target cell killing. In parallel experiments we have determined that both drugs increased the expression of p53 in tumor cells. However, that increase observed only after 48 hr of treatment and therefore could not contribute to observed sensitization of tumor cells to CTLs. To determine the effect of the combined treatment in vivo, mammary carcinoma TUBO was established s.c. in BALB/c mice. Dendritic cell vaccine alone slowed down tumor growth, which was consistent with previous results obtained by many laboratories. Paclitaxel had similar effect. However, in both cases tumor growth resumed in about a week...

show abstract

“…Chitosan, a deacetylation derivative of chitin, is a natural linear alkaline polysaccharide ( Figure 3(e)). It is a particularly attractive cationic polymer for biomedical applications due to its good biocompatibility, biodegradability, negligible immunogenicity, and low toxicity [65,66]. The primary amine groups in repeated glucosamine unit of chitosan can be protonated under acidic conditions.…”

Section: Cationic Polymersmentioning

confidence: 99%

Nanocarriers for siRNA delivery to overcome cancer multidrug resistance

Meng

Yin

2013

Chin. Sci. Bull.

View full text Add to dashboard Cite

Multidrug resistance (MDR) is an extremely complexed phenomenon in tumor chemotherapy and is one of the major obstacles for successful treatment. Discovery of RNA interference (RNAi) offers a new strategy with great potential to reverse MDR. Specific genes, which contribute to the emerging of MDR, can be silenced by RNAi. However, many natural barriers have to be overcome for efficient and safe delivery of siRNA. In recent years, the various kinds of nanocarriers, such as liposomes, cationic polymers, and inorganic materials, have been developed to deliver siRNA and show good results in reversing MDR. This review mainly summarizes the barriers in siRNA delivery and recent progress in designing nanotechnology-based siRNA delivery systems to overcome tumor MDR.cationic polymers, inorganic carriers, liposomes, multidrug resistance, nanocarriers, siRNA delivery Citation:Meng Q S, Yin Q, Li Y P. Nanocarriers for siRNA delivery to overcome cancer multidrug resistance.

show abstract

A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine

Cited by 108 publications

References 21 publications

Nanog signaling in cancer promotes stem-like phenotype and immune evasion

Nanog signaling in cancer promotes stem-like phenotype and immune evasion

A Direct Synergistic Effect of Immunotherapy and Chemotherapy as a New Paradigm in Treatment of Breast Cancer

Nanocarriers for siRNA delivery to overcome cancer multidrug resistance

Contact Info

Product

Resources

About